All News

Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.

Your daily dose of the clinical news you may have missed.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

Adults receiving the highest dose achieved 2 times the reduction in EASI scores vs placebo with responses emerging as early as day 8 of treatment.

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.

Your daily dose of the clinical news you may have missed.

The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.

Data for GC reduction and improved A4 levels were consistent across subgroups stratified by sex, race, age, BMI, and baseline A4 levels, according to Neurocrine Biosciences.